G1 Therapeutics Initiates Phase II Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment

G1 Therapeutics, Inc. announced that the company has initiated a Phase II, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response.